Evergreen Capital Management LLC Buys 3,178 Shares of AbbVie Inc. $ABBV

Evergreen Capital Management LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,578 shares of the company’s stock after acquiring an additional 3,178 shares during the period. Evergreen Capital Management LLC’s holdings in AbbVie were worth $12,174,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ABBV. Marshall & Sullivan Inc. WA purchased a new position in shares of AbbVie during the 2nd quarter valued at $25,000. Evolution Wealth Management Inc. bought a new stake in AbbVie during the second quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. purchased a new stake in shares of AbbVie during the second quarter worth about $36,000. Finally, Delos Wealth Advisors LLC bought a new stake in AbbVie during the 2nd quarter valued at approximately $39,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Down 1.1%

ABBV opened at $214.38 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a 50-day moving average of $226.80 and a 200 day moving average of $216.28. The firm has a market cap of $378.89 billion, a P/E ratio of 162.41, a P/E/G ratio of 0.89 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a report on Thursday. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, UBS Group reiterated a “neutral” rating on shares of AbbVie in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $247.84.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.